Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines

Journal of the National Cancer Institute

Volumn 91, Issue 5, 1999, Pages 429-433

  Ross, Douglas D ^a   Yang, Weidong ^g   Abruzzo, Lynne V ^g   Dalton, William S ^b   Schneider, Erasmus ^c   Lage, Hermann ^d   Dietel, Manfred ^d   Greenberger, Lee ^e   Cole, Susan P C ^f   Doyle, L Austin ^g  

^a UNIVERSITY OF MARYLAND   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c WADSWORTH CENTER   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e PFIZER INC   (United States)

^f QUEEN S UNIVERSITY   (Canada)

^g Bressler Research Bldg ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; VERAPAMIL; VINCA ALKALOID;

ARTICLE; BREAST CANCER; COLON CARCINOMA; FIBROSARCOMA; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MYELOMA; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOUTHERN BLOTTING; STOMACH CARCINOMA; TREATMENT OUTCOME;

EID: 0033518874     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.5.429     Document Type: Article

References (20)

1. Croop JM, Guild BC, Gros P, Housman DE. Genetics of multidrug resistance: relationship of a cloned gene to the complete multidrug resistant phenotype. Cancer Res 1987;47:5982-8.
2. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994;54:5902-10.
3. Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, et al. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer 1991;63:923-9.
4. Futscher BW, Abbaszadegan MR, Domann F, Dalton WS. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharmacol 1994;47:1601-6.
5. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C, et al. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdrl) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 1992;52:6175-81.
6. Yang CH, Cowan K, Schneider E. Reselection of a mitoxantrone-resistant breast carcinoma cell line with mitoxantrone results in a parallel increase in cross-resistance to camptothecin analogues [abstract]. Proc Am Assoc Cancer Res 1996;37:308.
7. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 1998;58:5850-8.
8. Dietel M, Arps H, Lage H, Niendorf A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 1990;50:6100-6.
9. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL, Fojo AT. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 1990;265:10073-80.
10. Lee JS, Scala S, Matsumoto Y, Dickstein B, Robey R, Zhan Z, et al. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem 1997;65:513-26.
11. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998;95:15665-70.
12. Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res 1989;49:4542-9.
13. Cowan KH, Goldsmith ME, Levine RM, Aitken SC, Douglass E, Clendeninn N, et al. Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem 1982;257:15079-86.
14. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 1994;54:152-8.
15. Fairchild CR, Ivy PS, Kao-Shan CS, Whang-Peng J, Rosen N, Israel MA, et al. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 1987;47:5141-8.
16. Yu Q, Mirski SEL, Sparks KE, Cole SPC. Two COOH-terminal truncated cytoplasmic forms of topoisomerase IIα in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing. Biochemistry 1997;36:5868-77.
17. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
18. Kellner U, Hutchinson L, Seidel A, Lage H, Danks MK, Dietel M, et al. Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma in the absence of P-glycoprotein. Int J Cancer 1997;71:817-24.
19. Holm PS, Scanlon KJ, Dietel M. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br J Cancer 1994;70:239-43.
20. Yang CH, Horton JK, Cowan KH, Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 1995;55: 4004-9.